COMMENTARY
Gordon L. Amidon: Very Sustained Drug Absorption
Maureen D. Donovan,
James E. Polli,
Peter Langguth,
Ikumi Tamai,
Balvinder Vig, Lawrence X. Yu,
Maureen D. Donovan
College of Pharmacy, University of Iowa, Iowa City, Iowa
Search for more papers by this authorCorresponding Author
James E. Polli
School of Pharmacy, University of Maryland, Baltimore, Maryland
Telephone: +410-706-8292; Fax: +410-706-5017; E-mail: [email protected]Search for more papers by this authorPeter Langguth
Institut fuer Pharmazie, Johannes Gutenberg-Universitaet, Mainz, Germany
Search for more papers by this authorIkumi Tamai
Faculty of Pharmacy, Kanazawa University, Kanazawa, Japan
Search for more papers by this authorLawrence X. Yu
Food and Drug Administration, Rockville, Maryland
Search for more papers by this authorMaureen D. Donovan,
James E. Polli,
Peter Langguth,
Ikumi Tamai,
Balvinder Vig, Lawrence X. Yu,
Maureen D. Donovan
College of Pharmacy, University of Iowa, Iowa City, Iowa
Search for more papers by this authorCorresponding Author
James E. Polli
School of Pharmacy, University of Maryland, Baltimore, Maryland
Telephone: +410-706-8292; Fax: +410-706-5017; E-mail: [email protected]Search for more papers by this authorPeter Langguth
Institut fuer Pharmazie, Johannes Gutenberg-Universitaet, Mainz, Germany
Search for more papers by this authorIkumi Tamai
Faculty of Pharmacy, Kanazawa University, Kanazawa, Japan
Search for more papers by this authorLawrence X. Yu
Food and Drug Administration, Rockville, Maryland
Search for more papers by this authorFirst published: 05 June 2015
REFERENCES
- 1Higuchi WI, Nelson E, Wagner JG. 1964. Solubility and dissolution rates in reactive media. J Pharm Sci 53: 333–335.
- 2Levy G, Nelson E. 1965. Theoretical relationship between dose, elimination rate, and duration of pharmacologic effect of drugs. J Pharm Sci 54: 812.
- 3Nelson E. 1965. Kinetic considerations in pharmacogenetic studies of drug metabolism. Life Sci 4: 949–953.
- 4Nelson EK. 1965. Field medical care—‘Farther and faster and finer’ with unique army hospital unit. Hosp Top 43: 45–48.
- 5Nelson E. 1965. Studies on the crystalluria potential of sulfamethoxydiazine. Chemotherapy 10: 145–151.
- 6Marglin A, Merrifield RB. 1966. The synthesis of bovine insulin by the solid phase method. J Am Chem Soc 88: 5051–5052.
- 7Merrifield RB, Stewart JM. 1965. Automated peptide synthesis. Nature 207: 522–523.
- 8Merrifield RB. 1965. Solid-phase peptide syntheses. Endeavour 24: 3–7.
- 9Merrifield RB. 1965. Automated synthesis of peptides. Science 150: 178–185.
- 10Merrifield RB. 1964. Solid-phase peptide synthesis. 3. An improved synthesis of bradykinin. Biochemistry 3: 1385–1390.
- 11Stehle RG, Higuchi WI. 1967. Diffusional model for transport rate studies across membranes. J Pharm Sci 56: 1367–1368.
- 12Higuchi WI, Mir NA, Desai SJ. 1965. Dissolution rates of polyphase mixtures. J Pharm Sci 54: 1405–1410.
- 13Higuchi WI, Rowe EL, Hiestand EN. 1963. Dissolution rates of finely divided drug powders. II. Micronized methyl-prednisolone. J Pharm Sci 52: 162–164.
- 14Higuchi WI, Hiestand EN. 1963. Dissolution rates of finely divided drug powders. I. Effect of a distribution of particle sizes in a diffusion-controlled process. J Pharm Sci 52: 67–71.
- 15Bird RB, Stewart WE, Lightfoot EN. 2002. Transport phenomena. 2nd ed. New York: Wiley.
10.1115/1.1424298 Google Scholar
- 16Amidon GL, Sinko PJ, Fleisher D. 1988. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res 5: 651–654.
- 17Dressman JB, Amidon GL, Fleisher D. 1985. Absorption potential: Estimating the fraction absorbed for orally administered compounds. J Pharm Sci 74: 588–589.
- 18Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. 2014. The biopharmaceutics classification system: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci 57: 152–163.
- 19Amidon GL, Kou J, Elliott RL, Lightfoot EN. 1980. Analysis of models for determining intestinal wall permeabilities. J Pharm Sci 69: 1369–1373.
- 20Radwan A, Wagner M, Amidon GL, Langguth P. 2014. Bio-predictive tablet disintegration: Effect of water diffusivity, fluid flow, food composition and test conditions. Eur J Pharm Sci 57: 273–279.
- 21Krieg BJ, Taghavi SM, Amidon GL, Amidon GE. 2014. In vivo predictive dissolution: Transport analysis of the CO, bicarbonate in vivo buffer system. J Pharm Sci 103: 3473–3490.
- 22Tsume Y, Incecayir T, Song X, Hilfinger JM, Amidon GL. 2014. The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: Enhanced membrane permeability and enzymatic stability. Eur J Pharm Biopharm 86: 514–523.
- 23Mudie DM, Murray K, Hoad CL, Pritchard SE, Garnett MC, Amidon GL, Gowland PA, Spiller RC, Amidon GE, Marciani L. 2014. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm 11: 3039–3047.
- 24Tsume Y, Borras Bermejo B, Amidon GL. 2014. The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs. Pharmaceuticals 7: 169–191.
- 25Xu H, Sabit H, Amidon GL, Showalter HD. 2013. An improved synthesis of a fluorophosphonate-polyethylene glycol-biotin probe and its use against competitive substrates. Beilstein J Org Chem 9: 89–96.
- 26Sabit H, Dahan A, Sun J, Provoda CJ, Lee KD, Hilfinger JH, Amidon GL. 2013. Cytomegalovirus protease targeted prodrug development. Mol Pharm 10: 1417–1424.
- 27Dahan A, Wolk O, Kim YH, Ramachandran C, Crippen GM, Takagi T, Bermejo M, Amidon GL. 2013. Purely in silico BCS classification: Science based quality standards for the world's drugs. Mol Pharm 10: 4378–4390.
- 28Tsume Y, Amidon GL. 2012. The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme. Molecules 17: 3672–3689.
- 29Smith DE, Rowland M, Giacomini KM, Amidon GL. 2012. Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong! Pharm Res 29: 2345–2353.
- 30Dahan A, Lennernas H, Amidon GL. 2012. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm 9: 1847–1851.
- 31Tsume Y, Amidon GL. 2012. Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenates. J Pharm Pharm Sci 15: 433–446.
- 32Gupta SV, Gupta D, Sun J, Dahan A, Tsume Y, Hilfinger J, Lee KD, Amidon GL. 2011. Enhancing the intestinal membrane permeability of zanamivir: A carrier mediated prodrug approach. Mol Pharm 8: 2358–2367.
- 33Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL. 2010. Enabling the intestinal absorption of highly polar antiviral agents: Ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm 7: 1223–1234.
- 34Tsume Y, Amidon GL. 2010. The biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm 7: 1235–1243.
- 35Dahan A, Miller JM, Hilfinger JM, Yamashita S, Yu LX, Lennernas H, Amidon GL. 2010. High-permeability criterion for BCS classification: Segmental/pH dependent permeability considerations. Mol Pharm 7: 1827–1834.
- 36Dahan A, Amidon GL. 2010. MRP2 mediated drug–drug interaction: Indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 386: 216–220.
- 37Tehler U, Nelson CH, Peterson LW, Provoda CJ, Hilfinger JM, Lee KD, McKenna CE, Amidon GL. 2010. Puromycin-sensitive aminopeptidase: An antiviral prodrug activating enzyme. Antivir Res 85: 482–489.
- 38Mudie DM, Amidon GL, Amidon GE. 2010. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 7: 1388–1405.
- 39Gupta D, Gupta SV, Lee KD, Amidon GL. 2009. Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol Pharm 6: 1604–1611.
- 40Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL. 2009. Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J Control Release 137: 31–37.
- 41Dahan A, Miller JM, Amidon GL. 2009. Prediction of solubility and permeability class membership: Provisional BCS classification of the world's top oral drugs. AAPS J 11: 740–746.
- 42Dahan A, Amidon GL. 2009. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 297: G371–G377.
- 43Higaki K, Choe SY, Lobenberg R, Welage LS, Amidon GL. 2008. Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. Eur J Pharm Biopharm 70: 313–325.
- 44Benet LZ, Amidon GL, Barends DM, Lennernas H, Polli JE, Shah VP, Stavchansky SA, Yu LX. 2008. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 25: 483–488.
- 45Lai L, Xu Z, Zhou J, Lee KD, Amidon GL. 2008. Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem 283: 9318–9327.
- 46Mittal S, Song X, Vig BS, Amidon GL. 2007. Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma. Pharm Res 24: 1290–1298.
- 47Mittal S, Tsume Y, Landowski CP, Lee KD, Hilfinger JM, Amidon GL. 2007. Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model. Eur J Pharm Biopharm 67: 752–758.
- 48Landowski CP, Lorenzi PL, Song X, Amidon GL. 2006. Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J Pharmacol Exp Ther 316: 572–580.
- 49Granero GE, Ramachandran C, Amidon GL. 2006. Rapid in vivo dissolution of ketoprofen: Implications on the biopharmaceutics classification system. Die Pharmazie 61: 673–676.
- 50Granero GE, Amidon GL. 2006. Stability of valacyclovir: Implications for its oral bioavailability. Int J Pharm 317: 14–18.
- 51Lorenzi PL, Landowski CP, Song X, Borysko KZ, Breitenbach JM, Kim JS, Hilfinger JM, Townsend LB, Drach JC, Amidon GL. 2005. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther 314: 883–890.
- 52Landowski CP, Vig BS, Song X, Amidon GL. 2005. Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther 4: 659–667.
- 53Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL. 2005. Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm 2: 157–167.
- 54Landowski CP, Song X, Lorenzi PL, Hilfinger JM, Amidon GL. 2005. Floxuridine amino acid ester prodrugs: Enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res 22: 1510–1518.
- 55Granero GE, Ramachandran C, Amidon GL. 2005. Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Drug Dev Ind Pharm 31: 917–922.
- 56Ettmayer P, Amidon GL, Clement B, Testa B. 2004. Lessons learned from marketed and investigational prodrugs. J Med Chem 47: 2393–2404.
- 57Landowski CP, Anderle P, Sun D, Sadee W, Amidon GL. 2004. Transporter and ion channel gene expression after Caco-2 cell differentiation using 2 different microarray technologies. AAPS J 6: e21.
- 58Kim I, Song X, Vig BS, Mittal S, Shin HC, Lorenzi PJ, Amidon GL. 2004. A novel nucleoside prodrug-activating enzyme: Substrate specificity of biphenyl hydrolase-like protein. Mol Pharm 1: 117–127.
- 59Kim I, Crippen GM, Amidon GL. 2004. Structure and specificity of a human valacyclovir activating enzyme: A homology model of BPHL. Mol Pharm 1: 434–446.
- 60Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, Hilfinger JM, Amidon GL. 2003. Amino acid ester prodrugs of floxuridine: Synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res 20: 1381–1388.
- 61Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. 2003. Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res 20: 749–756.
- 62Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, Amidon GL. 2003. Identification of a human valacyclovirase: Biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem 278: 25348–25356.
- 63Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. 2002. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res 19: 921–925.
- 64Martinez M, Amidon G, Clarke L, Jones WW, Mitra A, Riviere J. 2002. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. Adv Drug Deliv Rev 54: 825–850.
- 65Takamatsu N, Welage LS, Hayashi Y, Yamamoto R, Barnett JL, Shah VP, Lesko LJ, Ramachandran C, Amidon GL. 2002. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: Correlation with antral gastric motility. Eur J Pharm Biopharm 53: 37–47.
- 66Lee HJ, Amidon GL. 2002. The effect of enzyme inhibitor and absorption site following [D-ala2, D-leu5]enkephalin oral administration in rats. Biopharm Drug Dispos 23: 131–141.
- 67Takamatsu N, Kim ON, Welage LS, Idkaidek NM, Hayashi Y, Barnett J, Yamamoto R, Lipka E, Lennernas H, Hussain A, Lesko L, Amidon GL. 2001. Human jejunal permeability of two polar drugs: Cimetidine and ranitidine. Pharm Res 18: 742–744.
- 68Higaki K, Yamashita S, Amidon GL. 2001. Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn 28: 109–128.
- 69Han HK, Amidon GL. 2000. Targeted prodrug design to optimize drug delivery. AAPS Pharm Sci 2: E6.
- 70Jinno J, Oh D, Crison JR, Amidon GL. 2000. Dissolution of ionizable water-insoluble drugs: The combined effect of pH and surfactant. J Pharm Sci 89: 268–274.
10.1002/(SICI)1520-6017(200002)89:2<268::AID-JPS14>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 71Lobenberg R, Amidon GL. 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50: 3–12.
- 72Amidon GL, Walgreen Jr CR. 1999. “5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.” Pharm Res 16: 175.
- 73Oh DM, Han HK, Amidon GL. 1999. Drug transport and targeting. Intestinal transport. Pharm Biotechnol 12: 59–88.
- 74Yu LX, Amidon GL. 1999. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 186: 119–125.
- 75Rhie JK, Hayashi Y, Welage LS, Frens J, Wald RJ, Barnett JL, Amidon GE, Putcha L, Amidon GL. 1998. Drug marker absorption in relation to pellet size, gastric motility and viscous meals in humans. Pharm Res 15: 233–238.
- 76Croyle MA, Roessler BJ, Hsu CP, Sun R, Amidon GL. 1998. Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm Res 15: 1348–1355.
- 77Idkaidek NM, Amidon GL, Smith DE, Najib NM, Hassan MM. 1998. Determination of the population pharmacokinetic parameters of sustained-release and enteric-coated oral formulations, and the suppository formulation of diclofenac sodium by simultaneous data fitting using NONMEM. Biopharm Drug Dispos 19: 169–174.
10.1002/(SICI)1099-081X(199804)19:3<169::AID-BDD83>3.0.CO;2-C CAS PubMed Web of Science® Google Scholar
- 78Han HK, Stewart BH, Doherty AM, Cody WL, Amidon GL. 1998. In vitro stability and intestinal absorption characteristics of hexapeptide endothelin receptor antagonists. Life Sci 63: 1599–1609.
- 79Taki Y, Sakane T, Nadai T, Sezaki H, Amidon GL, Langguth P, Yamashita S. 1998. First-pass metabolism of peptide drugs in rat perfused liver. J Pharm Pharmacol 50: 1013–1018.
- 80Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon GL. 1998. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 15: 1154–1159.
- 81Lipka E, Spahn-Langguth H, Mutschler E, Amidon GL. 1998. In vivo non-linear intestinal permeability of celiprolol and propranolol in conscious dogs: Evidence for intestinal secretion. Eur J Pharm Sci 6: 75–81.
- 82Yu LX, Amidon GL. 1998. Saturable small intestinal drug absorption in humans: Modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm 45: 199–203.
- 83Covitz KM, Amidon GL, Sadee W. 1998. Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry 37: 15214–15221.
- 84Takamatsu N, Welage LS, Idkaidek NM, Liu DY, Lee PI, Hayashi Y, Rhie JK, Lennernas H, Barnett JL, Shah VP, Lesko L, Amidon GL. 1997. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res 14: 1127–1132.
- 85Covitz KM, Amidon GL, Sadee W. 1996. Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. Pharm Res 13: 1631–1634.
- 86Yu LX, Lipka E, Crison JR, Amidon GL. 1996. Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Deliv Rev 19: 359–376.
- 87Lipka E, Crison J, Amidon GL. 1996. Transmembrane transport of peptide type compounds: Prospects for oral delivery. J Control Release 39: 121–129.
- 88Sadee W, Drubbisch V, Amidon GL. 1995. Biology of membrane transport proteins. Pharm Res 12: 1823–1837.
- 89Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413–420.
- 90Su SF, Amidon GL. 1995. Investigation into the intestinal metabolism of [D-Ala1] peptide T amide: Implication for oral drug delivery. Biochim Biophys Acta 1245: 62–68.
- 91Lipka E, Lee ID, Langguth P, Spahn-Langguth H, Mutschler E, Amidon GL. 1995. Celiprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 23: 267–286.
- 92Langguth P, Merkle HP, Amidon GL. 1994. Oral absorption of peptides: The effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. Pharm Res 11: 528–535.
- 93Oh DM, Sinko PJ, Amidon GL. 1993. Characterization of the oral absorption of some beta-lactams: Effect of the alpha-amino side chain group. J Pharm Sci 82: 897–900.
- 94Oh DM, Curl RL, Amidon GL. 1993. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: A mathematical model. Pharm Res 10: 264–270.
- 95Sinko PJ, Leesman GD, Amidon GL. 1993. Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: Theoretical development and applications. Pharm Res 10: 271–275.
- 96Bai JP, Amidon GL. 1992. Structural specificity of mucosal-cell transport and metabolism of peptide drugs: Implication for oral peptide drug delivery. Pharm Res 9: 969–978.
- 97Sinko PJ, Leesman GD, Amidon GL. 1991. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res 8: 979–988.
- 98Friedman DI, Amidon GL. 1991. Oral absorption of peptides: Influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues. Pharm Res 8: 93–96.
- 99Oberle RL, Chen TS, Lloyd C, Barnett JL, Owyang C, Meyer J, Amidon GL. 1990. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 99: 1275–1282.
- 100Sirois PJ, Amidon GL, Meyer JH, Doty J, Dressman JB. 1990. Gastric emptying of nondigestible solids in dogs: A hydrodynamic correlation. Am J Physiol 258: G65–G72.
- 101Tsuji A, Tamai I, Nakanishi M, Amidon GL. 1990. Mechanism of absorption of the dipeptide alpha-methyldopa-phe in intestinal brush-border membrane vesicles. Pharm Res 7: 308–309.
- 102Friedman DI, Amidon GL. 1989. Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: Lisinopril and SQ 29,852. J Pharm Sci 78: 995–998.
- 103Hu M, Sinko PJ, deMeere AL, Johnson DA, Amidon GL. 1988. Membrane permeability parameters for some amino acids and beta-lactam antibiotics: Application of the boundary layer approach. J Theor Biol 131: 107–114.
- 104Stewart BH, Amidon GL, Brabec RK. 1986. Uptake of prodrugs by rat intestinal mucosal cells: Mechanism and pharmaceutical implications. J Pharm Sci 75: 940–945.
- 105Meyer JH, Dressman J, Amidon G. 1985. Hydrodynamic aspects of gastrointestinal (GI) transit. Nihon Heikatsukin Gakkai Zasshi 21(Suppl): 99–100.
- 106Amidon GL. 1985. Fluid mechanics and intestinal transit. Gastroenterology 88: 858.
- 107Amidon GL, Lee M, Lee H. 1983. Intestinal absorption of amino acid derivatives: Structural requirements for membrane hydrolysis. J Pharm Sci 72: 943–944.
- 108Hu M, Subramanian P, Mosberg HI, Amidon GL. 1989. Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: Carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa. Pharm Res 6: 66–70.
- 109Friedman DI, Amidon GL. 1989. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: Enalapril and fosinopril. Pharm Res 6: 1043–1047.
- 110Hu M, Amidon GL. 1988. Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci 77: 1007–1011.
- 111Merfeld AE, Mlodozeniec AR, Cortese MA, Rhodes JB, Dressman JB, Admidon GL. 1986. The effect of pH and concentration on alpha-methyldopa absorption in man. J Pharm Pharmacol 38: 815–822.
- 112Sinko PJ, Amidon GL. 1989. Characterization of the oral absorption of beta-lactam antibiotics. II. Competitive absorption and peptide carrier specificity. J Pharm Sci 78: 723–727.
- 113Sinko PJ, Amidon GL. 1988. Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: Determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res 5: 645–650.
- 114Kou JH, Fleisher D, Amidon GL. 1991. Calculation of the aqueous diffusion layer resistance for absorption in a tube: Application to intestinal membrane permeability determination. Pharm Res 8: 298–305.
- 115Knutson L, Hallgren R, Ahrenstedt O, Bengtsson U, Lavo B, Lennernas H, Wilhelmsson-Knutson T. 1994. Segmental intestinal perfusion. A “new” technique for human studies. Lakartidningen 91: 1941–1946.
- 116Lennernas H, Ahrenstedt O, Hallgren R, Knutson L, Ryde M, Paalzow LK. 1992. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 9: 1243–1251.
- 117Elliott RL, Amidon GL, Lightfoot EN. 1980. A convective mass transfer model for determining intestinal wall permeabilities: Laminar flow in a circular tube. J Theor Biol 87: 757–771.
- 118Amidon GL, Leesman GD, Elliott RL. 1980. Improving intestinal absorption of water-insoluble compounds: A membrane metabolism strategy. J Pharm Sci 69: 1363–1368.
- 119Mudie DM, Shi Y, Ping H, Gao P, Amidon GL, Amidon GE. 2012. Mechanistic analysis of solute transport in an in vitro physiological two-phase dissolution apparatus. Biopharm Drug Dispos 33: 378–402.
- 120Amidon KS, Langguth P, Lennernas H, Yu L, Amidon GL. 2011. Bioequivalence of oral products and the biopharmaceutics classification system: Science, regulation, and public policy. Clin Pharmacol Ther 90: 467–470.
- 121Matthews DM. 1987. Mechanisms of peptide transport. Beitrage Infusionsther Klin Ernahr 17: 6–53.
- 122Silk DB. 1977. Amino acid and peptide absorption in man. Ciba Found Symp: 15–29.
- 123Silk DB. 1974. Progress report. Peptide absorption in man. Gut 15: 494–501.
- 124Matthews DM. 1972. Intestinal absorption of amino acids and peptides. Proce Nutr Soc 31: 171–177.
- 125Amidon GL, Chang M, Fleisher D, Allen R. 1982. Intestinal absorption of amino acid derivatives: Importance of the free alpha-amino group. J Pharm Sci 71: 1138–1141.
- 126Mathews DM, Adibi SA. 1976. Peptide absorption. Gastroenterology 71: 151–161.
- 127Matthews DM, Crampton RF, Lis MT. 1968. Intestinal absorption of peptides. Lancet 2: 639–640.
- 128Park JY, Ho NF, Morozowich W. 1984. Physical model approach to gastrointestinal absorption of prostaglandins II: In situ rat intestinal absorption of dinoprost. J Pharm Sci 73: 1588–1594.
- 129Amidon GE, Higuchi WI, Ho NF. 1982. Theoretical and experimental studies of transport of micelle-solubilized solutes. J Pharm Sci 71: 77–84.
- 130Amidon GE, Ho NF, French AB, Higuchi WI. 1981. Predicted absorption rates with simultaneous bulk fluid flow in the intestinal tract. J Theor Biol 89: 195–210.
- 131Ho NF, Higuchi WI. 1974. Theoretical model studies of intestinal drug absorption. IV. Bile acid transport at premicellar concentrations across diffusion layer-membrane barrier. J Pharm Sci 63: 686–690.
- 132Ho NF, Higuchi WI, Turi J. 1972. Theoretical model studies of drug absorption and transport in the GI tract. 3. J Pharm Sci 61: 192–197.
- 133Johnson DA, Amidon GL. 1988. Determination of intrinsic membrane transport parameters from perfused intestine experiments: A boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. J Theor Biol 131: 93–106.
- 134Amidon GL, Merfeld AE, Dressman JB. 1986. Concentration and pH dependency of alpha-methyldopa absorption in rat intestine. J Pharm Pharmacol 38: 363–368.
- 135Fleisher D, Johnson KC, Stewart BH, Amidon GL. 1986. Oral absorption of 21-corticosteroid esters: A function of aqueous stability and intestinal enzyme activity and distribution. J Pharm Sci 75: 934–939.
- 136Fleisher D, Stewart BH, Amidon GL. 1985. Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting. Methods Enzymol 112: 360–381.
- 137Johnson K, Amidon GL, Pogany S. 1985. Solution kinetics of a water-soluble hydrocortisone prodrug: Hydrocortisone-21-lysinate. J Pharm Sci 74: 87–89.
- 138de Miranda P, Blum MR. 1983. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 12(Suppl B): 29–37.
- 139Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL. 1999. CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci 88: 347–350.
- 140Han HK, Oh DM, Amidon GL. 1998. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res 15: 1382–1386.
- 141Fei YJ, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron WF, Hediger MA. 1994. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature 368: 563–566.
- 142Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon GL. 2006. The suitability of an in situ perfusion model for permeability determinations: Utility for BCS class I biowaiver requests. Mol Pharm 3: 686–694.
- 143Foster DR, Gonzales JP, Amidon GL, Welage LS. 2009. Intestinal dipeptide absorption is preserved during thermal injury and cytokine treatment. JPEN J Parenter Enteral Nutr 33: 520–528.
- 144Lorenzi PL, Landowski CP, Brancale A, Song X, Townsend LB, Drach JC, Amidon GL. 2006. N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole. Drug Metab Dispos 34: 1070–1077.
- 145Song X, Vig BS, Lorenzi PL, Drach JC, Townsend LB, Amidon GL. 2005. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. J Med Chem 48: 1274–1277.
- 146Shin HC, Kim JS, Vig BS, Song X, Drach JC, Amidon GL. 2006. Interaction of intestinal nucleoside transporter hCNT2 with amino acid ester prodrugs of floxuridine and 2-bromo-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. Biol Pharm Bulletin 29: 247–252.
- 147Marsillach J, Suzuki SM, Richter RJ, McDonald MG, Rademacher PM, MacCoss MJ, Hsieh EJ, Rettie AE, Furlong CE. 2014. Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase. PloS One 9: e110054.
- 148McCully KS. 2015. Homocysteine and the pathogenesis of atherosclerosis. Expert Rev Clin Pharmacol 8: 211–219.
- 149Jakubowski H. 2004. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci 61: 470–487.
- 150Jakubowski H. 2000. Homocysteine thiolactone: Metabolic origin and protein homocysteinylation in humans. J Nutr 130: 377S–381S.
- 151Niphakis MJ, Cravatt BF. 2014. Enzyme inhibitor discovery by activity-based protein profiling. Ann Rev Biochem 83: 341–377.
